Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Clin Infect Dis. 2022 Apr 9;74(7):1315-1316. doi: 10.1093/cid/ciab705.

Authors

Affiliations

¹ CHU Toulouse, Hôpital Purpan, Virology Laboratory, Toulouse, France.
² INSERM UMR1291-CNRS UMR5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), Toulouse, France.
³ Occupational Diseases Department, Toulouse University Hospital, Toulouse, France.
⁴ Infectious and Tropical Diseases Department, Toulouse University Hospital, Toulouse, France.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neutralizing
Antibodies, Viral
BNT162 Vaccine
COVID-19* / prevention & control
Humans
SARS-CoV-2*
Vaccination

Substances

Antibodies, Neutralizing
Antibodies, Viral
BNT162 Vaccine

Associated data

ClinicalTrials.gov/NCT04385108